Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Payables (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Payables for 8 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 18.85% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 million, a 18.85% increase, with the full-year FY2024 number at $2.2 million, down 63.39% from a year prior.
  • Payables was $1.6 million for Q3 2025 at Whitehawk Therapeutics, down from $3.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.5 million in Q1 2023 to a low of $458658.0 in Q1 2021.
  • A 5-year average of $3.3 million and a median of $3.2 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: tumbled 75.06% in 2021, then surged 774.29% in 2022.
  • Whitehawk Therapeutics' Payables stood at $6.4 million in 2021, then plummeted by 45.35% to $3.5 million in 2022, then surged by 67.6% to $5.9 million in 2023, then plummeted by 63.39% to $2.2 million in 2024, then decreased by 24.36% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Payables are $1.6 million (Q3 2025), $3.3 million (Q2 2025), and $2.2 million (Q4 2024).